{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Quetiapine+or+Risperidone+%2B+placebo", "query": { "intervention": "Quetiapine or Risperidone + placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T17:02:59.619Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01052103", "title": "A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "LY2140023", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Denovo Biopharma LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 167, "start_date": "2010-01", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2022-09-07", "last_synced_at": "2026-10-07T17:02:59.619Z", "location_count": 4, "location_summary": "Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hoffman Estates", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01052103" }, { "nct_id": "NCT00325689", "title": "Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Quetiapine or Risperidone + Aripiprazole", "type": "DRUG" }, { "name": "Quetiapine or Risperidone + placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2006-07", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2013-11-08", "last_synced_at": "2026-10-07T17:02:59.619Z", "location_count": 48, "location_summary": "Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Granada Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00325689" }, { "nct_id": "NCT03557931", "title": "A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "ASP4345", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" }, { "name": "quetiapine", "type": "DRUG" }, { "name": "olanzapine", "type": "DRUG" }, { "name": "ziprasidone", "type": "DRUG" }, { "name": "aripiprazole", "type": "DRUG" }, { "name": "brexpiprazole", "type": "DRUG" }, { "name": "paliperidone", "type": "DRUG" }, { "name": "lurasidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 233, "start_date": "2018-07-13", "completion_date": "2019-10-21", "has_results": true, "last_update_posted_date": "2024-11-12", "last_synced_at": "2026-10-07T17:02:59.619Z", "location_count": 27, "location_summary": "Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Pico Rivera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03557931" }, { "nct_id": "NCT00509067", "title": "Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Galantamine", "type": "DRUG" }, { "name": "CDP-choline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 43, "start_date": "2007-11", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2018-04-11", "last_synced_at": "2026-10-07T17:02:59.619Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509067" }, { "nct_id": "NCT00061802", "title": "Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "risperidone, quetiapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 225, "start_date": "2003-06", "completion_date": "2004-02", "has_results": false, "last_update_posted_date": "2012-02-07", "last_synced_at": "2026-10-07T17:02:59.619Z", "location_count": 7, "location_summary": "San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Hoffman Est", "state": "Illinois" }, { "city": "Lake Charles", "state": "Louisiana" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Visakhapatnam", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061802" }, { "nct_id": "NCT00439634", "title": "Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "AVE1625", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 873, "start_date": "2007-02", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2016-05-18", "last_synced_at": "2026-10-07T17:02:59.619Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00439634" }, { "nct_id": "NCT01272765", "title": "Anti-psychotic Medication (Stable Dose) Weight Loss Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "IHBG-10", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "OTHER", "DIETARY_SUPPLEMENT" ], "sponsor": "Avera McKennan Hospital & University Health Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2012-03", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2012-06-01", "last_synced_at": "2026-10-07T17:02:59.619Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01272765" }, { "nct_id": "NCT03818256", "title": "A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Antipsychotic-induced Weight Gain (AIWG)" ], "interventions": [ { "name": "Miricorilant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 71, "start_date": "2019-12-04", "completion_date": "2022-07-06", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-07T17:02:59.619Z", "location_count": 27, "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03818256" }, { "nct_id": "NCT01272752", "title": "Anti-psychotic Medication (New Use) Weight Loss Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "IHBG-10", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Avera McKennan Hospital & University Health Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-04", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2012-06-01", "last_synced_at": "2026-10-07T17:02:59.619Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01272752" }, { "nct_id": "NCT03565068", "title": "A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "MK-8189", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Background AAP Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 75, "start_date": "2018-06-20", "completion_date": "2020-04-03", "has_results": true, "last_update_posted_date": "2021-03-29", "last_synced_at": "2026-10-07T17:02:59.619Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03565068" } ] }